Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
Mattia RossoCindy T GonzalezBrian C HealyShrishti SaxenaAnu PaulKjetil BjornevikJens KuhlePascal BenkertDavid LeppertCharles GuttmannRohit BakshiHoward L WeinerTanuja ChitinisPublished in: Annals of clinical and translational neurology (2020)
Our findings support sNfL as a marker of clinical relapses and Gd+ lesions. sNfL peaks in a 3-month window around Gd+ lesions. sNfL shows promise as a biomarker of neurological inflammation and possibly of simultaneous Gd+ lesions during a clinical relapse.